Oracle (ORCL) Announces Acquisition of ClearTrial
Tweet
Share
E-mailGet Alerts ORCL Hot Sheet
Price: $146.47 +3.10%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 0.7%
Revenue Growth %: +28.1%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 0.7%
Revenue Growth %: +28.1%
Join SI Premium – FREE
Oracle (Nasdaq: ORCL) today announced that it has entered into an agreement to acquire ClearTrial, a leading provider of cloud-based Clinical Trial Operations (CTO) applications that make the planning, sourcing, and tracking of clinical projects and financial performance faster and more accurate.
Terms of the agreement were not disclosed.
Terms of the agreement were not disclosed.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oracle (ORCL) October 175 calls active as share price up 3.6%
- General Fusion lists on Nasdaq via SPAC merger with $150M in cash
- TMCR raises $165M to acquire additional Mesabi iron ore royalty
Create E-mail Alert Related Categories
Mergers and AcquisitionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
